Search | Page 13 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Alan List, MD

    ... (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which ...

    Leadership Award last updated 05/02/2016 - 12:18pm.

  2. Pathogenesis of MDS: An overview of molecular and non-molecular aspects of the disease

    ... are currently three FDA-approved medications for MDS: lenalidomide , azacitidine , and decitabine .  Although these ...

    Research Review last updated 05/02/2016 - 9:14am.

  3. Sexuality and Intimacy

    ... symptoms. Immunomodulatory agents like lenalidomide (Revlimid®) can cause fatigue, nausea and joint pain. ...

    Page last updated 05/02/2016 - 10:09am.

  4. Myelofibrosis (MF)

    ... drugs such as thalidomide and the related drugs lenalidomide and pomalidomide, which in some patients may improve blood ...

    Topic section last updated 07/07/2016 - 3:16pm.

  5. Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

    ... , hematopoietic growth factors, Zarnestra, Lenalidomide , arsenic, Imatinib, and corticosteroids, suberoylanilide ...

    Clinical Trial last updated 06/03/2016 - 2:24pm.

  6. Dr. Vivienne Rebel reviews a recent study about p53 protein levels as a prognostic factor in MDS

    ... enrolled in a randomized trial, for which they received lenalidomide or a placebo .  P53 staining was performed on samples ... overall survival and a lower cytogenetic response rate to lenalidomide treatment (i.e., the disappearance of cells with abnormal ...

    Research Review last updated 05/02/2016 - 9:17am.

  7. Alan List, MD

    ... (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which ...

    Bio last updated 03/11/2016 - 1:41pm.

  8. Benjamin L. Ebert, MD, PhD

    ... Recent work has elucidated the mechanism of action of lenalidomide , a drug that acts by modulating the function of an ...

    Bio last updated 03/11/2016 - 1:41pm.

  9. Options for MDS patients beyond HMAs

    ... ; switching to the other of the two HMAs – preferably lenalidomide in the presence of deletion of the long arm of chromosome 5, ...

    Research Review last updated 05/02/2016 - 9:09am.

  10. Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy from the European Leukemianet Low Risk MDS (EUMDS) Registry

    ... colony-stimulating factor, hydroxyurea, or Revlimid® ( lenalidomide ). Patients’ median age was 73 years, and 59% were male. ...

    Research Review last updated 05/02/2016 - 9:27am.